Published in Eur J Nucl Med Mol Imaging on November 24, 2015
Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies. Int J Mol Sci (2016) 0.77
Tetraspanin 8 (TSPAN 8) as a potential target for radio-immunotherapy of colorectal cancer. Oncotarget (2017) 0.75
The Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair (86)Y and (90)Y. Pharmaceuticals (Basel) (2017) 0.75
Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys (2010) 4.33
Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med (1995) 3.50
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med (2013) 3.21
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther (2009) 2.36
(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med (2011) 2.01
Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. J Nucl Med (2007) 1.72
PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice. PLoS One (2007) 1.43
Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol (2012) 1.33
Pretargeted molecular imaging and radioimmunotherapy. Theranostics (2012) 1.31
Antibodies with infinite affinity. Proc Natl Acad Sci U S A (2001) 1.30
A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel (2009) 1.29
Antibodies against metal chelates. Nature (1985) 1.27
Quantitative imaging of bromine-76 and yttrium-86 with PET: a method for the removal of spurious activity introduced by cascade gamma rays. Med Phys (2003) 1.19
A semiempirical model of tumor pretargeting. Bioconjug Chem (2008) 1.16
Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system. Cancer Imaging (2011) 1.09
124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET. J Nucl Med (2011) 1.08
Predicting response to radioimmunotherapy from the tumor microenvironment of colorectal carcinomas. Cancer Res (2007) 1.08
Radioimmunotherapy of human tumours. Nat Rev Cancer (2015) 1.07
Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy. Int J Oncol (1996) 1.06
Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol (1994) 1.06
Tumor size: effect on monoclonal antibody uptake in tumor models. J Nucl Med (1986) 1.06
Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy. Br J Cancer (1995) 1.04
Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. Nucl Med Biol (2010) 0.98
Quantitative Imaging of Yttrium-86 with PET. The Occurrence and Correction of Anomalous Apparent Activity in High Density Regions. Clin Positron Imaging (2000) 0.98
Effect of small-molecule-binding affinity on tumor uptake in vivo: a systematic study using a pretargeted bispecific antibody. Mol Cancer Ther (2012) 0.94
Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft. J Nucl Med (2001) 0.93
Radiation Dose Assessment for I-131 Therapy of Thyroid Cancer Using I-124 PET Imaging. Clin Positron Imaging (1999) 0.92
A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin Cancer Res (2000) 0.91
Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging. J Nucl Med (2011) 0.90
Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Mol Cancer Ther (2014) 0.89
Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam. J Nucl Med (2000) 0.89
Phase I radioimmunotherapy trial with iodine-131--labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin Colorectal Cancer (2002) 0.88
Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy. Mol Imaging Biol (2011) 0.88
A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance. Protein Eng Des Sel (2012) 0.85
Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM). Br J Cancer (1996) 0.85
Irreversibly binding anti-metal chelate antibodies: Artificial receptors for pretargeting. J Inorg Biochem (2006) 0.84
131I radioimmunotherapy and fractionated external beam radiotherapy: comparative effectiveness in a human tumor xenograft. J Nucl Med (1999) 0.80
PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. Eur J Nucl Med Mol Imaging (2015) 0.79
Higher dose and dose-rate in smaller tumors result in improved tumor control. Cancer Invest (2003) 0.79
New anti-Cu-TETA and anti-Y-DOTA monoclonal antibodies for potential use in the pre-targeted delivery of radiopharmaceuticals to tumor. Hybridoma (1998) 0.76